The added value of using mutational profiling in addition to cytology in diagnosing aggressive pancreaticobiliary disease: review of clinical cases at a single center

BMC Gastroenterology

Sydney D Finkelstein²  Nadim G Haddad¹  Mary K Sidawy⁴  Mindi A Styn³  Lindsay L Freed³  Sara A Jackson³  Nidhi Malhotra¹ 

[1]Medstar Georgetown University Hospital, Division of Gastroenterology, Washington, DC, USA

[2]Department of Pathology, Drexel University, Philadelphia, PA, USA

[3]RedPath Integrated Pathology, Inc., Pittsburgh, PA, USA

[4]Department of Pathology, Medstar Georgetown University Hospital, Washington, DC, USA

关键词: Molecular analysis;    Pancreatic cancer;    Pancreatic cyst;   

Others  :  1121863
DOI  :  10.1186/1471-230X-14-135

 received in 2014-01-17, accepted in 2014-07-28,  发布年份 2014

【 摘 要 】

Background

This study aimed to better understand the supporting role that mutational profiling (MP) of DNA from microdissected cytology slides and supernatant specimens may play in the diagnosis of malignancy in fine-needle aspirates (FNA) and biliary brushing specimens from patients with pancreaticobiliary masses.

Methods

Cytology results were examined in a total of 30 patients with associated surgical (10) or clinical (20) outcomes. MP of DNA from microdissected cytology slides and from discarded supernatant fluid was analyzed in 26 patients with atypical, negative or indeterminate cytology.

Results

Cytology correctly diagnosed aggressive disease in 4 patients. Cytological diagnoses for the remaining 26 were as follows: 16 negative (9 false negative), 9 atypical, 1 indeterminate. MP correctly determined aggressive disease in 1 false negative cytology case and confirmed a negative cytology diagnosis in 7 of 7 cases of non-aggressive disease. Of the 9 atypical cytology cases, MP correctly diagnosed 7 as positive and 1 as negative for aggressive disease. One specimen that was indeterminate by cytology was correctly diagnosed as non-aggressive by MP. When first line malignant (positive) cytology results were combined with positive second line MP results, 12/21 cases of aggressive disease were identified, compared to 4/21 cases identified by positive cytology alone.

Conclusions

When first line cytology results were uncertain (atypical), questionable (negative), or not possible (non-diagnostic/indeterminate), MP provided additional information regarding the presence of aggressive disease. When used in conjunction with first line cytology, MP increased detection of aggressive disease without compromising specificity in patients that were difficult to diagnose by cytology alone.

【 授权许可】

   
2014 Malhotra et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
• [2]Carpizo DR, Allen PJ, Brennan MF: Current management of cystic neoplasms of the pancreas. Surgeon 2008, 6(5):298-307.
• [3]Fasanella KE, McGrath K: Cystic lesions and intraductal neoplasms of the pancreas. Best Pract Res Clin Gastroenterol 2009, 23(1):35-48.
• [4]Deng H, Shi J, Wilkerson M, Meschter S, Dupree W, Lin F: Usefulness of S100P in diagnosis of adenocarcinoma of pancreas on fine-needle aspiration biopsy specimens. Am J Clin Pathol 2008, 129(1):81-88.
• [5]Lin F, Staerkel G: Cytologic criteria for well differentiated adenocarcinoma of the pancreas in fine-needle aspiration biopsy specimens. Cancer 2003, 99:44-50.
• [6]Xiao GQ: Fine-needle aspiration of cystic pancreatic mucinous tumor: oncotic cell as an aiding diagnostic feature in paucicellular specimens. Diagn Pathol 2009, 37:111-116.
• [7]Woolf KMW, Liang H, Sletten ZJ, Russell DK, Bonfiglio TA, Zhou Z: False-negative rate of endoscopic ultrasound-guided fine-needle aspiration for pancreatic solid and cystic lesions with matched surgical resections as the gold standard: one Institution’s experience. Cancer Cytopathol 2013. doi:10.1002/cncy.21299
• [8]Siddiqui AA, Kowalski TE, Shahid H, O'Donnell S, Tolin J, Loren DE, Infantolino A, Hong SK, Eloubeidi MA: False-positive EUS-guided FNA cytology for solid pancreatic lesions. Gastrointest Endosc 2011, 74(3):535-540.
• [9]Wood MD, Horst JA, Bibbo M: Weeding atypical glandular cell look-alikes from the true atypical lesions in liquid-based Pap tests: a review. Diagn Pathol 2007, 35(1):12-17.
• [10]Khalid A, Zahid M, Finkelstein SD, LeBlanc JK, Kaushik N, Ahmad N, Brugge WR, Edmundowicz SA, Hawes RH, McGrath KM: Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study. Gastrointest Endosc 2009, 69(6):1095-1102.
• [11]Krishnamurti U, Sasatomi E, Swalsky PA, Finkelstein SD, Ohori NP: Analysis of loss of heterozygosity in atypical and negative bile duct brushing cytology specimens with malignant outcome: are “false-negative” cytologic findings a representation of morphologically subtle molecular alterations? Arch Pathol Lab Med 2007, 131(1):74-80.
• [12]Lapkus O, Gologan O, Liu Y, Swalsky PA, Wilson MM, Finkelstein SD, Silverman JF: Determination of sequential mutation accumulation in pancreas and bile duct brushing cytology. Mod Pathol 2006, 19(7):907-913.
• [13]Mertz H: K-ras mutations correlate with atypical cytology and elevated CEA levels in pancreatic cystic neoplasms. Dig Dis Sci 2011, 56(7):2197-2201.
• [14]Schoedel KE, Finkelstein SD, Ohori NP: K-Ras and microsatellite marker analysis of fine-needle aspirates from intraductal papillary mucinous neoplasms of the pancreas. Diagn Pathol 2006, 34(9):605-608.
• [15]Toll AD, Kowalski T, Loren D, Bibbo M: The added value of molecular testing in small pancreatic cysts. Jop 2010, 11(6):582-586.
• [16]Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, et al.: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321(5897):1801-1806.
• [17]Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, Lucas DJ, Niknafs N, Guthrie VB, Maitra A, Argani P, Offerhaus GJ, Roa JC, Roberts LR, Gores GJ, Popescu I, Alexandrescu ST, Dima S, Fassan M, Simbolo M, Mafficini A, Capelli P, Lawlor RT, Ruzzenente A, Guglielmi A, Tortora G, de Braud F, Scarpa A, Jarnagin W, Klimstra D, Karchin R, et al.: Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet 2013, 45(12):1470-1473.
• [18]Gamblin TC, Finkelstein SD, Upsal N, Kaye JD, Blumberg D: Microdissection-based allelotyping: a novel technique to determine the temporal sequence and biological aggressiveness of colorectal cancer. Am Surg 2006, 72(5):445-453.
• [19]Lin X, Finkelstein SD, Zhu B, Ujevich BJ, Silverman JF: Loss of heterozygosities in Barrett esophagus, dysplasia, and adenocarcinoma detected by esophageal brushing cytology and gastroesophageal biopsy. Cancer 2009, 117(1):57-66.
• [20]Shi C, Hong SM, Lim P, Kamiyama H, Khan M, Anders RA, Goggins M, Hruban RH, Eshleman JR: KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin. Mol Cancer Res MCR 2009, 7(2):230-236.
• [21]Taii A, Hamada S, Kataoka K, Yasukawa S, Sonoyama T, Okanoue T, Yanagisawa A: Correlations between p53 gene mutations and histologic characteristics of pancreatic ductal carcinoma. Pancreas 2009, 38(2):e60-e67.
• [22]Finkelstein SD, Bibbo M, Loren DE, Siddiqui AA, Solomides C, Kowalski TE, Ellsworth E: Molecular analysis of centrifugation supernatant fluid from pancreaticobiliary duct samples can improve cancer detection. Acta Cytol 2012, 56(4):439-447.
• [23]Deftereos G, Finkelstein SD, Jackson SA, Ellsworth EM, Krishnamurti U, Liu Y, Silverman JF, Binkert CR, Ujevich BA, Mohanty A: The value of mutational profiling of the cytocentrifugation supernatant fluid from fine-needle aspiration of pancreatic solid mass lesions. Mod Pathol 2013. In press
• [24]Anker P, Mulcahy H, Chen XQ, Stroun M: Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 1999, 18(1):65-73.
• [25]Aung KL, Board RE, Ellison G, Donald E, Ward T, Clack G, Ranson M, Hughes A, Newman W, Dive C: Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours. Hugo J 2010, 4(1–4):11-21.
• [26]Bremnes RM, Sirera R, Camps C: Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up? Lung Cancer 2005, 49(1):1-12.
• [27]Cabral R, Neto J, Carvalho MG: Circulating DNA as a biomarker for early detection of cancer: A brief update with an emphasis on lung cancer. Open Lung Cancer J 2010, 3:38-44.
• [28]Mulcahy H, Farthing MJ: Diagnosis of pancreatico-biliary malignancy: detection of gene mutations in plasma and stool. Ann Oncol 1999, 10(Suppl 4):114-117.
• [29]Narayan A, Carriero NJ, Gettinger SN, Kluytenaar J, Kozak KR, Yock TI, Muscato NE, Ugarelli P, Decker RH, Patel AA: Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing. Cancer Res 2012, 72(14):3492-3498.
• [30]No HJ, Kim K, Park KH, Kim YB: Cell-free DNA level as a prognostic biomarker for epithelial ovarian cancer. Anticancer Res 2012, 32:3467-3471.
• [31]Schwarzenbach H, Eichelser C, Kropidlowski J, Janni W, Rack B, Pantel K: Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression. Clin Cancer Res 2012, 18(20):5719-5730.
• [32]Zhou J, Shi YH, Fan J: Circulating cell-free nucleic acids: promising biomarkers of hepatocellular carcinoma. Semin Oncol 2012, 39:440-448.
• [33]Ostrovnaya I, Seshan VE, Olshen AB, Begg CB: Clonality: an R package for testing clonal relatedness of two tumors from the same patient based on their genomic profiles. Bioinformatics 2011, 27(12):1698-1699.
• [34]Ryozawa S, Kitoh H, Gondo T, Urayama N, Yamashita H, Ozawa H, Yanai H, Okita K: Usefulness of endoscopic ultrasound-guided fine-needle aspiration biopsy for the diagnosis of pancreatic cancer. J Gastroenterol 2005, 40:907-911.
• [35]Almonguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988, 53:549-554.
• [36]Khalid A, McGrath KM, Zahid M, Wilson M, Brody D, Swalsky P, Moser AJ, Lee KK, Slivka A, Whitcomb DC, Finkelstein S: The role of pancreatic cyst fluid molecular analysis in predicting cyst pathology. Clin Gastroenterol Hepatol Off Clin Practice J Am Gastroenterol Assoc 2005, 3(10):967-973.
• [37]Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, DePinho RA: Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006, 20:1218-1249.
• [38]Iacobuzio-Donahue CA, van der Heijden MS, Baumgartner MR, Troup WJ, Romm JM, Doheny K, Pugh E, Yeo CJ, Goggins MG, Hruban RH, Kern SE: Large-scale allelotype of pancreaticobiliary carcinoma provides quantitative estimates of genome-wide allelic loss. Cancer Res 2004, 64:871-875.
• [39]Hahn SA, Seymour AB, Hoque ATMS, Schutte M, da Costa LT, Redston MS, Caldas C, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE: Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res 1995, 55:4670-4675.
• [40]Gleeson FC, Kipp BR, Caudill JL, Clain JE, Clayton AC, Halling KC, Henry MR, Rajan E, Topazian MD, Wang KK, Wiersema MJ, Zhang J, Levy MJ: False positive endoscopic ultrasound fine needle aspiration cytology: incidence and risk factors. Gut 2010, 59(5):586-593.
• [41]Hewitt MJ, McPhail MJ, Possamai L, Dhar A, Vlavianos P, Monahan KJ: EUS-guided FNA for diagnosis of solid pancreatic neoplasms: a meta-analysis. Gastrointest Endosc 2012, 75(2):319-331.